855 results on '"Blanco, Julià"'
Search Results
202. DBP rs7041 and DHCR7 rs3829251 are Linked to CD4+ Recovery in HIV Patients on Antiretroviral Therapy.
203. Association between HIV replication and cholesterol in peripheral blood mononuclear cells in HIV-infected patients interrupting HAART
204. Myalgic encephalomyelitis/chronic fatigue Syndrome (ME/CFS): Investigating care practices pointed out to disparities in diagnosis and treatment across European Union
205. The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy
206. IL7RA rs6897932 polymorphism is associated with better CD4+ T-cell recovery in HIV infected patients starting combination antiretroviral therapy
207. Glutaminolysis and lipoproteins are key factors in late immune recovery in successfully treated HIV-infected patients
208. Immunological and virological study of enfuvirtide-treated HIV-positive patients
209. Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication
210. Stromal-cell-derived factor 1 prevents the emergence of the syncytium-inducing phenotype of HIV-1 in vivo
211. Cell-Surface-Expressed HIV-1 Envelope Induces the Death of CD4 T Cells during GP41-Mediated Hemifusion-like Events
212. Apoptosis Control in Syncytia Induced by the HIV Type 1-Envelope Glycoprotein Complex: Role of Mitochondria and Caspases
213. Mitochondrial Control of Cell Death Induced by HIV-1-Encoded Proteins
214. Pigs are not susceptible to SARS‐CoV‐2 infection but are a model for viral immunogenicity studies.
215. The implication of the chemokine receptor CXCR4 in HIV-1 envelope protein-induced apoptosis is independent of the G protein-mediated signalling
216. Chemokine and chemokine receptor expression after combined anti-HIV-1 interleukin-2 therapy
217. The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype
218. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome – Evidence for an autoimmune disease
219. Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs
220. HIV-1 Nef Targets HDAC6 to Assure Viral Production and Virus Infection
221. CD4 recovery is associated with genetic variation in IFNγ and IL19 genes
222. Different pattern of stool and plasma gastrointestinal damage biomarkers during primary and chronic HIV infection
223. Combined assessment of peritumoral Th1/Th2 polarization and peripheral immunity as a new biomarker in the prediction of BCG response in patients with high-risk NMIBC
224. Glutaminolysis and lipoproteins are key factors in late immune recovery in successfully treated HIV-infected patients
225. Switching From a Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen: A Randomized Clinical Trial to Determine the Effect on Peripheral Blood and Ileum Biopsies From Antiretroviral Therapy–suppressed Human Immunodeficiency Virus–infected Individuals
226. Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney
227. Nitric oxide production in renal cells by immune complexes: Role of kinases and nuclear factor-κB
228. Enzymatic and extraenzymatic role of ecto-adenosine deaminase in lymphocytes
229. Pauci-immune extracapillary glomerulonephritis and atheromatous embolization
230. On the steps of cell-to-cell HIV transmission between CD4 T cells
231. HIV transfer between CD4 T cells does not require LFA-1 binding to ICAM-1 and is governed by the interaction of HIV envelope glycoprotein with CD4
232. A baseline metabolomic signature is associated with immunological CD4+ T-Cell recovery after 36 months of art in HIV-infected patients
233. CD4+ and CD8+ T Cell Death during Human Immunodeficiency Virus Infection in Vitro
234. A cytokine pattern that differentiates pre- from post- seroconversion phases of primary HIV infection
235. The HIV-1 gp120 inhibits the binding of adenosine deaminase to CD26 by a mechanism modulated by CD4 and CXCR4 expression
236. Antibodies and Antibody Derivatives: New Partners in HIV Eradication Strategies
237. Secreted IgD Amplifies Humoral T Helper 2 Cell Responses by Binding Basophils via Galectin-9 and CD44
238. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome – Evidence for an autoimmune disease
239. Viral Characteristics Associated with the Clinical Nonprogressor Phenotype Are Inherited by Viruses from a Cluster of HIV-1 Elite Controllers
240. Dynamics of CD4 and CD8 T-Cell Subsets and Inflammatory Biomarkers during Early and Chronic HIV Infection in Mozambican Adults
241. Renal expression of parathyroid hormone-related protein (PTHrP) and PTH/PTHrP receptor in a rat model of tubulointerstitial damage
242. Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif
243. Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B
244. Elevated humoral response to cytomegalovirus in HIV-infected individuals with poor CD4+ T-cell immune recovery
245. Immunologic Insights on the Membrane Proximal External Region: A Major Human Immunodeficiency Virus Type-1 Vaccine Target
246. Preserved immune functionality and high CMV-specific T-cell responses in HIV-infected individuals with poor CD4+ T-cell immune recovery
247. IP-10 Levels as an Accurate Screening Tool to Detect Acute HIV Infection in Resource-Limited Settings
248. The European ME/CFS Biomarker Landscape project: an initiative of the European network EUROMENE
249. Interferon-γ–Inducible Protein 10 (IP-10) as a Screening Tool to Optimize Human Immunodeficiency Virus RNA Monitoring in Resource-Limited Settings
250. Higher levels of IL-6, CD4 turnover and Treg frequency are already present before cART in HIV-infected subjects with later low CD4 recovery
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.